ZEO Scientifix Inc. has released its financial results for the quarter ending July 31, 2025. The company reported revenues of $1.306 million for the three months ended July 31, 2025, representing an increase of $215,000 or 19.7% from the $1.091 million reported for the same period in 2024. This revenue growth was primarily driven by increased revenues from the PPX service platform, partially offset by a decline in sales of the company's allogenic aesthetic biologic products. ZEO Scientifix Inc. continues to focus on the development of innovative biological therapeutics for degenerative diseases and regenerative medicine, with products like Zofin and Patient Pure X being central to its offerings. The company remains dependent on additional investment capital to fund ongoing operating expenses and research and development efforts, as well as to conduct required clinical studies. Management anticipates that the company will continue to rely on external funding sources for the near future to support its operations and product development initiatives.